| DFTX | Definium Therapeutics Inc Ordinary Shares | 12.86% |
| CMPS | Compass Pathways PLC ADR | 11.47% |
| ATAI | AtaiBeckley Inc | 10.48% |
| RLMD | Relmada Therapeutics Inc | 6.84% |
| NRXP | NRX Pharmaceuticals Inc Ordinary Shares | 6.07% |
| NBIX | Neurocrine Biosciences Inc | 4.39% |
| HELP.NE | Helus Pharma Inc Ordinary Shares | 4.36% |
| GHRS | GH Research PLC | 4.32% |
| ALKS | Alkermes PLC | 4.30% |
| ANRO | Alto Neuroscience Inc | 4.21% |
The fund is an actively managed ETF that seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that derive at least 50% of their net revenue from or devote 50% of their assets to psychedelic drugs and derivatives that have economic characteristics similar to such securities. The fund primarily invests in publicly listed life sciences companies focused on psychedelic medicines as well as other companies with activities in the psychedelics business. The fund is non-diversified.
AdvisorShares Psychedelics ETF · Issued by AdvisorShares
No recent news for PSIL. The ingest cron pulls every 15 minutes during market hours.